AKTX — Akari Therapeutics Plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1541157 ·
Last close
$9.76
Market Cap
$18.99M
52W High
$46.00
52W Low
$3.02
ADV30
87,477
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,602,000 | -4,807,000 | 38,624,000 | 7,694,000 | 20,029,000 |
| Mar 2026 | 0 | — | -3,628,000 | -14,455,000 | 33,889,000 | 2,768,000 | 19,509,000 |
| Dec 2025 | 0 | — | -3,227,000 | -5,298,000 | 47,892,000 | 5,203,000 | 19,564,000 |
| Sep 2025 | 0 | — | -2,224,000 | -6,400,000 | 45,376,000 | 2,484,000 | 22,689,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,906,000
Investing CF
—
Financing CF
$11,091,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-279,005,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-28,955,000
Pretax Income TTM
$-29,910,000
Interest Exp TTM
$955,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -12,095,000 | -17,298,000 | 47,892,000 | 19,564,000 | 28,328,000 | -10,568,000 |
| Dec 2024 | 0 | -16,647,000 | -19,791,000 | 50,562,000 | 28,333,000 | 22,229,000 | -12,552,000 |
| Dec 2023 | 0 | -16,806,000 | -10,008,000 | 4,355,000 | 4,584,000 | -229,000 | -16,432,000 |
| Dec 2022 | 0 | -23,088,000 | -17,748,000 | 13,832,000 | 12,041,000 | 1,791,000 | -21,504,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-14.00
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.50 · spot: $10.68 · call volume: 4 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATOS | ATOSSA THERAPEUTICS, INC. | $18.96M | $1.90 | — |
| MRKR | Marker Therapeutics, Inc. | $19.17M | $1.15 | — |
| NEUP | Neuphoria Therapeutics Inc. | $19.73M | $3.65 | — |
| MCUJF | MEDICURE INC | $19.83M | $1.90 | — |
| PTN | PALATIN TECHNOLOGIES INC | $17.97M | $10.10 | — |
News headlines (Yahoo Finance, 1h cache)
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
2026-09-08 13:15 · Yahoo
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-27 13:01 · Yahoo
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
2026-08-18 12:53 · Yahoo
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
2026-08-13 20:15 · Yahoo
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
2026-08-04 12:50 · Yahoo
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
2026-07-22 12:40 · Yahoo
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
2026-07-21 11:05 · Yahoo
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
2026-07-07 12:55 · Yahoo
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
2026-06-29 12:45 · Yahoo
European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading
2026-06-15 15:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.